Please sign in to follow a disease.
Genetic score may sharpen heart risk prediction for millions
NCT ID NCT07039123
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This trial tests whether adding a polygenic risk score (a DNA-based estimate of heart disease risk) to standard risk assessment helps better identify who needs preventive measures like statins or lifestyle changes. About 205 adults aged 40–69 with intermediate cardiovascular risk will either receive standard risk information or have their risk refined with the genetic score. Researchers will compare changes in risk scores and preventive actions over 18 months.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Polygenic Risk Score for Coronary Artery Disease (PRS-CAD)
- What this could lead to
- If successful, this approach could help doctors identify who truly needs preventive treatments like statins, reducing heart attacks in people at intermediate risk.
- What could go wrong
- The trial is relatively small (205 participants) and focuses on risk prediction, not direct treatment. The added value of PRS over standard risk tools may be modest, and results may not apply to all populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
205 people
The number who actually took part.
- Started
-
Jul 2025
- Expected to finish
-
Nov 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
40 to 69 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * 40-69 years old * Intermediate cardiovascular risk based on SCORE2 or SCORE2-Diabetes * Able to give informed consent (understanding German or French or with an interpreter) * Written Informed Consent Exclusion Criteria: * Patient treated under lipid-lowering therapy (defined as statin, ezetimib, bempedoïc acid, PCSK-9 inhibitors) * History of previous cardiovascular disease: coronary artery disease (CAD), peripheral artery disease and ischemic stroke (including transitory ischemic stroke). * Chronic kidney disease (CKD) define as an estimated glomerular filtration rate (eGFR) of less than 30 ml/min or less than 60 ml/min with albuminuria patients with diabetes and end organ damage (classified as very high risk according to ESC guidelines). * Other participation in a clinical study related to CV risk or lifestyle interventions (e.g. diet, smoking cessation...) * Life expectancy of less than one year
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Primary prevention of cardiovascular disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Fribourgeois (HFR)
Fribourg, Switzerland
-
University of Bern, Institute of Primary Health Care (BIHAM)
Bern, 3012, Switzerland